Feugiat nulla facilisis at vero eros et curt accumsan et iusto odio dignissim qui blandit praesent luptatum zzril.
+ (123) 1800-453-1546
info@example.com

Related Posts

Title Image

Research

  • Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study. Smit MA, van Pelt GW, Roodvoets A, Meershoek- Klein Kranenbarg E, Putter H, et al.. JMIR Res Protoc. 2019 Jun 14;8(6):e13464

2019

  • Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial. Zunder S, van der Wilk P, Gelderblom H, Dekker T, Mancao C, et al. Cell Oncol (Dordr). 2019 Oct;42(5):717-725.
  • The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. van Wyk HC, Roseweir A, Alexander P, Park JH, Horgan PG, et al. Ann Surg Oncol. 2019 Oct 11.
  • Tumour Budding and Tumour Stroma Ratio are Reliable Predictors for Death and Recurrence in Elderly Stage I Colon Cancer Patients. Zengin M. Pathol Res Pract. 2019 Nov;215(11):152635
  • The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. Roseweir AK, Clark J, McSorley ST, vanWyk HC, Quinn JA, et al. Int J Cancer. 2019 May 1;144(9):2320-2329.
  • Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. Geessink OGF, Baidoshvili A, Klaase JM, Ehteshami Bejnordi B, Litjens GJS, et al. Cellular Oncology. 2019 February.

2018

  • Scoring the tumour-stroma ratio in colon cancer: Procedure and recommendations. van Pelt GW, Kjaer-Frifeldt S, van Krieken JHJM, Al Dieri R, Morreau H, Tollenaar RAEM, et al. Virchows Archiv. 2018 Oct; 473(4):405-412
  • Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Zunder SM, van Pelt GW, Gelderblom HJ, Mancao C, Putter H, Tollenaar RA, et al. British Journal of Cancer. 2018
  • The tumour-stroma ratio in colon cancer; the biological role and its prognostic impact. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken J, Tollenaar R, et al. Histopathology. 2018 Aug;73(2):197-206.
  • The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial. Huijbers A, van Pelt GW, Kerr RS, Johnstone EC, Tollenaar R, Kerr DJ, et al. J Surg Oncol. 2018 Apr;117(5):1043-1048.
  • Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer? Eriksen AC, Andersen JB, Lindebjerg J, dePont Christensen R, Jansen TF, Kjaer-Frifeldt S, et al. Diagn Pathology. 2018 Mar;13(1):20
  • Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. Hutchins GGA, Treanor D, Wright A, Handley K, Magill L, Tinkler-Hundal E, et al. 2018;72(3):391-404.
  • The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. Eriksen AC, Sorensen FB, Lindebjerg J,Hager H, dePont Christensen R, Kjaer-Frifeldt S, et al. International Journal of Colorectal Disease. 2018 Aug;33(8):115-1124

2017

  • Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer. Jakubowska K, Kisielewski W, Kanczuga-Koda L, Koda M, Famulski W. Oncol Lett. 2017;14(3):3869-77.
  • High tumor stroma proportion is a worse prognostic factor in colorectal cancer. Flam J, Gugic D, Bensic M, Tomic S, Rajc J.Acta Clin Croat. 2017 Jan;56(1)73-79.
  • Prognostic markers for colorectal cancer; estimating ploidy and stroma. Danielsen HE, Hveem TS, Domingo E, Pradhan M, Kleppe A, Syvertsen RA, et al. Ann Oncol. 2017.
  • Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. Hansen TF, Kjaer-Frifeldt S, Lindebjerg J, Rafaelsen SR, Jensen LH, Jakobsen A, et al. Acta Oncol. 2017:1-6.
  • Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study. Hynes SO, Coleman HG, Kelly PJ, Irwin S, O’Neill RF, Gray RT, et al. 2017;71(1):12-26.
  • Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. Park JH, van Wyk H, Roxburgh CSD, Horgan PG, Edwards J, McMillan DC. Br J Cancer. 2017;116(11):1444-50.
  • Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study. Scheer R, Baidoshvili A, Zoidze S, Elferink MAG, Berkel AEM, Klaase JM, et al. World J Gastrointest Oncol. 2017;9(12):466-74.

2016

  • Stroma-High Lymph Node Involvement Predicts Poor Survival More Accurately for Patients with Stage III Colon Cancer. Van Pelt GW, Hansen TF,Bastiaannet E, Frifeldt SK, Van Krieken JH, et al. J Med Surg Pathol 2016; 1:116.
  • Are disseminated tumor cells in bone marrow and tumor-stroma ratio clinically applicable for patients undergoing surgical resection of primary colorectal cancer? The Leiden MRD study. Vogelaar FJ, van Pelt GW, van Leeuwen AM, Willems JM, Tollenaar RA, Liefers GJ, et al. Cell Oncol (Dordr). 2016;39(6):537-44.

2014

  • The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS. Ann Oncol. 2014;25(3):644-51.

2013

  • The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, et al. Ann Oncol. 2013;24(1):179-85

2010

  • The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, et al. Br J Cancer. 2010;102(10):1519-23.

2009

  • Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, et al. Cell Oncol. 2009;31(3):169-78.

2007

  • The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, et al. Cell Oncol. 2007;29(5):387-98.

2019

  • The intra-tumoural stroma in patients with breast cancer increases with age. Vangangelt KMH, Kramer CJH, Bastiaannet E, Putter H, Cohen D, van Pelt GW, et al. Breast Cancer Res Treat. 2019

2018

  • The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tollenaar RAEM, Mesker WE. Breast Cancer Res Treat. 2018 Oct
  • The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients. Vangangelt KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, Dekker TJA, Kuppen PJK , et al. Int J Cancer. 2018 Jul 6.
  • Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, Smit V, et al. Breast Cancer Res Treat. 2018 Apr;168(3):601-612.

2017

  • The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study. Roeke T, Sobral-Leite M, Dekker TJA, Wesseling J, Smit V, Tollenaar R, et al. Breast Cancer Res Treat. 2017;166(2):435-45.

2014

  • The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Gujam FJ, Edwards J, Mohammed ZM, Going JJ, McMillan DC. Br J Cancer. 2014;111(1):157-65
  • The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer.Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, et al. Br J Cancer  2014; 110 (7):1744-1747.
  • Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT, et al. Breast Cancer Res Treat. 2013;139(2):371-9.

2012

  • The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA. Eur J Surg Oncol. 2012;38(4):307-13.

2011

  • Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, et al. Breast Cancer Res Treat. 2011;125(3):687-96.

2018

  • The ratio of cancer cells to stroma within the invasive area is histologic prognostic parameter of lung adenocarcinoma.Ichikawa T, Aokage K, Sugano M, Miyoshi T, Kojima M, Fujii S, et al. Lung Cancer 2018; 118:30-35.

2017

  • Tumour-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival. Xi K, Wen Y, Zhu C, Yu X, Qin R, Zhang X, et al. J Thorac Dis 2017; 9(10):4017-4026.

2015

  • Tumor-stroma ratio is an independent predictor for survival in NSCLC. Zhang T, Xu J, Shen H, Dong W, Ni Y, Du J. Int J Clin Exp Pathol. 2015;8(9):11348-55.

2013

  • [Tumor-stroma ratio is an independent prognostic factor of non-small cell lung cancer].Wang Z, Liu H, Zhao R, Zhang H, Liu C, Song Y. Zhongguo Fei Ai Za Zhi. 2013;16(4):191-6.

2019

  • Prognostic significance of tumor budding, tumor-stroma ratio, cell nests size, and stroma type in laryngeal and pharyngeal squamous cell carcinomas. Karpathiou G, Vieville M, Gavid M, Camy F, Dumollard JM, et al. Head Neck. 2019 Jan;1-10

2018

  • Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers. Almangush A, Heikkinen I, Bakhti N, Makinen LK, Kauppila JH, Pukkila M, et al. Histopathology. 2018.
  • Prognostic impact of tumor-stroma ratio in oral squamous cell carcinoma – A pilot study. Niranjan KC, Sarathy NA. Annals of Diagnostic Pathology 2018; 35:56-61.

2014

  • The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer. Oncol Res Treat. Zhang XL, Jiang C, Zhang ZX, Liu F, Zhang F, Cheng YF. 2014;37(9):480-4.

2016

  • Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial.Hale MD, Nankivell M, Hutchins GG, Stenning SP, Langley RE, Mueller W, et al. Oncotarget. 2016;7(47):77565-75.

2012

  • Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. Wang K, Ma W, Wang J, Yu L, Zhang X, Wang Z, et al. J Thorac Oncol. 2012;7(9):1457-61.

2011

  • Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. Courrech Staal EF, Smit VT, van Velthuysen ML, Spitzer-Naaykens JM, Wouters MW, Mesker WE, et al. Eur J Cancer. 2011;47(3):375-82.

2010

  • The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Courrech Staal EF, Wouters MW, van Sandick JW, Takkenberg MM, Smit VT, Junggeburt JM, et al. Eur J Cancer. 2010;46(4):720-8.

2018

  • Tumor microenvironmental factors have prognostic significances in advanced gastric cancer.Ahn B, Chae YS, Kim CH, Lee Y, Lee JH, Kom JY. APMIS (Journal of pathology, microbiology and immunology). Sept 2018
  • Tumour-stroma ratio and prognosis in gastric adenocarcinoma.Kemi N, Eskuri M, Herva A, Leppänen J, Huhta H, Helminen O, et al. British Journal of Cancer. 2018

2017

  • The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system.Peng C, Liu J, Yang G, Li Y. J Gastroenterol. 2017.
  • Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients.Aurello P, Berardi G, Giulitti D, Palumbo A, Tierno SM, Nigri G, et al. Surgeon. 2017 Dec; 15(6):329-335.
  • Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas.Lee D, Ham IH, Son SY, Han SU, Kim YB, Hur H.Gastric Cancer. 2017 Jul;20(4):591-601.

2019

  • Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Leppänen J, Lindholm V, Isohookana J, Haapasaari KM, Karihtala P, et al. Pancreas. 2019 Jan;48(1):43-48.

2017

  • Prognostic significance of the tumor-stroma ratio in gallbladder cancer. Li H, Yuan SL, Han ZZ, Huang J, Cui L, et al. Neoplasma 64; 2017.

2015

  • Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. Lv Z, Cai X, Weng X, Xiao H, Du C, Cheng J, et al. Surgery 2015;158(1):142-50.

2015

  • Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer. Chen Y, Zhang L, Liu W, Liu X. Biomed Res Int. 2015;2015:589301.
  • Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. Pongsuvareeyakul T, Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Intaraphet S, Siriaunkgul S. Asian Pac J Cancer Prev 2015; 16 (10):4363-4368.
  • The prognostic significance of tumour-stroma ratio in endometrial carcinoma. Panayiotou H, Orsi NM, Thygesen HH, Wright AI, Winder M, Hutson R, et al. BMC Cancer. 2015;15:955.

2014

  • Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma. Liu J, Liu J, Li J, Chen Y, Guan X, Wu X, et al. Gynecol Oncol. 2014;132(1):81-6.

2019

  • The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma. Zou MX, Zheng BW, Liu FS, Wang XB, Hu JR, Huang W, et al. Neurosurgery. 2019 Sep 9.

Meta-analysis

  • Tumor-stroma ratio (TSR) as a potential novel predictor of prognosis in digestive system cancers: A meta-analysis. Zhang R, Song W, Wang K, Zou S. Clin Chim Acta. 2017;472:64-8.
  • Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis.Wu J, Liang C, Chen M, Su W. Oncotarget. 2016 Oct 18;7(42):68954-68965.

Reviews

  • The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tollenaar RAEM, Mesker WE. Breast Cancer Res Treat. 2018 Oct
  • The tumour-stroma ratio in colon cancer; the biological role and its prognostic impact. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken J, Tollenaar R, et al. Histopathology. 2018 Aug;73(2):197-206.

2019

  • Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial. Zunder S, van der Wilk P, Gelderblom H, Dekker T, Mancao C, et al. Cell Oncol (Dordr). 2019 Oct;42(5):717-725.
  • The intra-tumoural stroma in patients with breast cancer increases with age. Vangangelt KMH, Kramer CJH, Bastiaannet E, Putter H, Cohen D, van Pelt GW, et al. Breast Cancer Res Treat. 2019

2018

  • The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Kramer CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tollenaar RAEM, Mesker WE. Breast Cancer Res Treat. 2018 Oct
  • Scoring the tumour-stroma ratio in colon cancer: Procedure and recommendations. van Pelt GW, Kjaer-Frifeldt S, van Krieken JHJM, Al Dieri R, Morreau H, Tollenaar RAEM, et al. Virchows Archiv. 2018 Oct; 473(4):405-412
  • Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Zunder SM, van Pelt GW, Gelderblom HJ, Mancao C, Putter H, Tollenaar RA, et al. British Journal of Cancer. 2018
  • The tumour-stroma ratio in colon cancer; the biological role and its prognostic impact. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken J, Tollenaar R, et al. Histopathology. 2018 Aug;73(2):197-206.
  • The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients. Vangangelt KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, Dekker TJA, Kuppen PJK , et al. Int J Cancer. 2018 Jul 6.
  • The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.Huijbers A, van Pelt GW, Kerr RS, Johnstone EC, Tollenaar R, Kerr DJ, et al. J Surg Oncol. 2018 Apr;117(5):1043-1048.
  • Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. Vangangelt KMH, van Pelt GW, Engels CC, Putter H, Liefers GJ, Smit V, et al. Breast Cancer Res Treat. 2018 Apr;168(3):601-612.

2017

  • The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study. Roeke T, Sobral-Leite M, Dekker TJA, Wesseling J, Smit V, Tollenaar R, et al. Breast Cancer Res Treat. 2017;166(2):435-45.

2016

  • Stroma-High Lymph Node Involvement Predicts Poor Survival More Accurately for Patients with Stage III Colon Cancer. Van Pelt GW, Hansen TF,Bastiaannet E, Frifeldt SK, Van Krieken JH, et al. J Med Surg Pathol 2016; 1:116.
  • Are disseminated tumor cells in bone marrow and tumor-stroma ratio clinically applicable for patients undergoing surgical resection of primary colorectal cancer? The Leiden MRD study. Vogelaar FJ, van Pelt GW, van Leeuwen AM, Willems JM, Tollenaar RA, Liefers GJ, et al. Cell Oncol (Dordr). 2016;39(6):537-44.

2013

  • Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT, et al. Breast Cancer Res Treat. 2013;139(2):371-9.
  • The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, et al. Ann Oncol. 2013;24(1):179-85

2011

  • Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. Courrech Staal EF, Smit VT, van Velthuysen ML, Spitzer-Naaykens JM, Wouters MW, Mesker WE, et al. Eur J Cancer. 2011;47(3):375-82.
  • Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, et al. Breast Cancer Res Treat. 2011;125(3):687-96.

2010

  • The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Courrech Staal EF, Wouters MW, van Sandick JW, Takkenberg MM, Smit VT, Junggeburt JM, et al. Eur J Cancer. 2010;46(4):720-8.

2009

  • Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, et al. Cell Oncol. 2009;31(3):169-78.

2007

  • The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, et al. Cell Oncol. 2007;29(5):387-98.

2019

  • The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. van Wyk HC, Roseweir A, Alexander P, Park JH, Horgan PG, et al. Ann Surg Oncol. 2019 Oct 11.
  • Tumour Budding and Tumour Stroma Ratio are Reliable Predictors for Death and Recurrence in Elderly Stage I Colon Cancer Patients. Zengin M. Pathol Res Pract. 2019 Nov;215(11):152635
  • The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. Roseweir AK, Clark J, McSorley ST, vanWyk HC, Quinn JA, et al. Int J Cancer. 2019 May 1;144(9):2320-2329.
  • The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma. Zou MX, Zheng BW, Liu FS, Wang XB, Hu JR, Huang W, et al. Neurosurgery. 2019 Sep 9.
  • Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Leppänen J, Lindholm V, Isohookana J, Haapasaari KM, Karihtala P, et al. Pancreas. 2019 Jan;48(1):43-48.
  • Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. Geessink OGF, Baidoshvili A, Klaase JM, Ehteshami Bejnordi B, Litjens GJS, et al. Accepted February 2019 in Cellular Oncology.
  • Prognostic significance of tumor budding, tumor-stroma ratio, cell nests size, and stroma type in laryngeal and pharyngeal squamous cell carcinomas. Karpathiou G, Vieville M, Gavid M, Camy F, Dumollard JM, et al. Head Neck. 2019 Jan;1-10

2018

  • Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer? Eriksen AC, Andersen JB, Lindebjerg J, dePont Christensen R, Jansen TF, Kjaer-Frifeldt S, et al. Diagn Pathology. 2018 Mar;13(1):20
  • Tumor microenvironmental factors have prognostic significances in advanced gastric cancer. Ahn B, Chae YS, Kim CH, Lee Y, Lee JH, Kom JY. APMIS (Journal of pathology, microbiology and immunology). Sept 2018
  • Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Kemi N, Eskuri M, Herva A, Leppänen J, Huhta H, Helminen O, et al. British Journal of Cancer. 2018
  • Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers. Almangush A, Heikkinen I, Bakhti N, Makinen LK, Kauppila JH, Pukkila M, et al. Histopathology. 2018.
  • Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. Hutchins GGA, Treanor D, Wright A, Handley K, Magill L, Tinkler-Hundal E, et al. Histopathology. 2018;72(3):391-404.
  • The ratio of cancer cells to stroma within the invasive area is histologic prognostic parameter of lung adenocarcinoma. Ichikawa T, Aokage K, Sugano M, Miyoshi T, Kojima M, Fujii S, et al. Lung Cancer 2018; 118:30-35.
  • The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. Eriksen AC, Sorensen FB, Lindebjerg J,Hager H, dePont Christensen R, Kjaer-Frifeldt S, et al. International Journal of Colorectal Disease. 2018 Aug;33(8):115-1124
  • Prognostic impact of tumor-stroma ratio in oral squamous cell carcinoma – A pilot study. Niranjan KC, Sarathy NA. Annals of Diagnostic Pathology 2018; 35:56-61.

2017

  • High tumor stroma proportion is a worse prognostic factor in colorectal cancer. Flam J, Gugic D, Bensic M, Tomic S, Rajc J.Acta Clin Croat. 2017 Jan;56(1)73-79.
  • Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer. Jakubowska K, Kisielewski W, Kanczuga-Koda L, Koda M, Famulski W. Oncol Lett. 2017;14(3):3869-77.
  • Prognostic markers for colorectal cancer; estimating ploidy and stroma. Danielsen HE, Hveem TS, Domingo E, Pradhan M, Kleppe A, Syvertsen RA, et al. Ann Oncol. 2017.
  • Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. Hansen TF, Kjaer-Frifeldt S, Lindebjerg J, Rafaelsen SR, Jensen LH, Jakobsen A, et al. Acta Oncol. 2017:1-6.
  • Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study. Hynes SO, Coleman HG, Kelly PJ, Irwin S, O’Neill RF, Gray RT, et al. Histopathology. 2017;71(1):12-26.
  • Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. Park JH, van Wyk H, Roxburgh CSD, Horgan PG, Edwards J, McMillan DC. Br J Cancer. 2017;116(11):1444-50.
  • The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system.Peng C, Liu J, Yang G, Li Y. J Gastroenterol. 2017.
  • Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study. Scheer R, Baidoshvili A, Zoidze S, Elferink MAG, Berkel AEM, Klaase JM, et al. World J Gastrointest Oncol. 2017;9(12):466-74.
  • Tumor-stroma ratio (TSR) as a potential novel predictor of prognosis in digestive system cancers: A meta-analysis. Zhang R, Song W, Wang K, Zou S. Clin Chim Acta. 2017;472:64-8.
  • Tumour-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival. Xi K, Wen Y, Zhu C, Yu X, Qin R, Zhang X, et al. J Thorac Dis 2017; 9(10):4017-4026.
  • Prognostic significance of the tumor-stroma ratio in gallbladder cancer. Li H, Yuan SL, Han ZZ, Huang J, Cui L, Jiang CQ, Zhang Y. Neoplasma 64; 2017.
  • Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients.Aurello P, Berardi G, Giulitti D, Palumbo A, Tierno SM, Nigri G, et al. Surgeon. 2017 Dec; 15(6):329-335.
  • Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas. Lee D, Ham IH, Son SY, Han SU, Kim YB, Hur H.Gastric Cancer. 2017 Jul;20(4):591-601.

2016

  • Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Hale MD, Nankivell M, Hutchins GG, Stenning SP, Langley RE, Mueller W, et al. Oncotarget. 2016;7(47):77565-75.
  • Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis. Wu J, Liang C, Chen M, Su W. Oncotarget. 2016 Oct 18;7(42):68954-68965.

2015

  • Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer. Chen Y, Zhang L, Liu W, Liu X. Biomed Res Int. 2015;2015:589301.
  • Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation. Lv Z, Cai X, Weng X, Xiao H, Du C, Cheng J, et al. Surgery 2015;158(1):142-50.
  • Tumor-stroma ratio is an independent predictor for survival in NSCLC. Zhang T, Xu J, Shen H, Dong W, Ni Y, Du J. Int J Clin Exp Pathol. 2015;8(9):11348-55.
  • Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. Pongsuvareeyakul T, Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Intaraphet S, Siriaunkgul S. Asian Pac J Cancer Prev 2015; 16 (10):4363-4368.
  • The prognostic significance of tumour-stroma ratio in endometrial carcinoma. Panayiotou H, Orsi NM, Thygesen HH, Wright AI, Winder M, Hutson R, et al. BMC Cancer. 2015;15:955.

2014

  • The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. Gujam FJ, Edwards J, Mohammed ZM, Going JJ, McMillan DC. Br J Cancer. 2014;111(1):157-65.
  • Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma. Liu J, Liu J, Li J, Chen Y, Guan X, Wu X, et al. Gynecol Oncol. 2014;132(1):81-6.
  • The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS. Ann Oncol. 2014;25(3):644-51.
  • The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer. Oncol Res Treat. Zhang XL, Jiang C, Zhang ZX, Liu F, Zhang F, Cheng YF. 2014;37(9):480-4.
  • The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer.Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, et al. Br J Cancer  2014; 110 (7):1744-1747.

2013

  • [Tumor-stroma ratio is an independent prognostic factor of non-small cell lung cancer]. Wang Z, Liu H, Zhao R, Zhang H, Liu C, Song Y. Zhongguo Fei Ai Za Zhi. 2013;16(4):191-6.

2012

  • The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA. Eur J Surg Oncol. 2012;38(4):307-13.
  • Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. Wang K, Ma W, Wang J, Yu L, Zhang X, Wang Z, et al. J Thorac Oncol. 2012;7(9):1457-61.

2010

  • The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, et al. Br J Cancer. 2010;102(10):1519-23.